Sugi Predict

Sugi Predict / Compounds / SCHEMBL6347109

SCHEMBL6347109

SCHEMBL6347109

CCCS(=O)(=O)NC1CCCCC1(O)c1ccc(OCc2cc(F)cc(F)c2)cc1

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ADAM17 P78536 5/20 0.38
▸ MMP2 P08253 1/20 0.38
▸ MMP9 P14780 1/20 0.38
▸ MMP14 P50281 1/20 0.38
▸ RORC P51449 1/20 0.37
▸ GSK3B P49841 1/20 0.37
▸ BACE1 P56817 1/20 0.37
▸ MMP1 P03956 10/20 0.36
▸ MMP13 P45452 2/20 0.36
▸ AR P10275 1/20 0.34
▸ MAOB P27338 1/20 0.33
▸ PSEN1 P49768 1/20 0.33
▸ PSEN2 P49810 1/20 0.33
▸ APH1B Q8WW43 1/20 0.33
▸ NCSTN Q92542 1/20 0.33
▸ APH1A Q96BI3 1/20 0.33
▸ PSENEN Q9NZ42 1/20 0.33
▸ ELOVL6 Q9H5J4 1/20 0.33
▸ TP53 P04637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6240201 0.97 ADAM17 (0.38) ADAM17MMP2MMP9MMP14RORC
SCHEMBL6345535 0.89 RORC (0.38) ADAM17MMP2MMP9MMP14RORC
SCHEMBL6348256 0.88 AR (0.44) ADAM17MMP2RORCMMP1MMP13
SCHEMBL6347105 0.86 ADAM17 (0.38) ADAM17MMP2MMP9MMP14RORC
SCHEMBL6239468 0.85 AR (0.45) ADAM17RORCMMP1MMP13AR
SCHEMBL6344011 0.84 PSEN1 (0.39) RORCPSEN1PSEN2APH1BNCSTN
SCHEMBL6348039 0.83 ADAM17 (0.39) ADAM17MMP2MMP9MMP14RORC
SCHEMBL6240195 0.83 ADAM17 (0.39) ADAM17MMP2MMP9MMP14RORC
SCHEMBL6344031 0.83 ADAM17 (0.39) ADAM17MMP2MMP9MMP14RORC
SCHEMBL6244914 0.82 SLC6A4 (0.42) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6900353-B2 Cyclopentyl sulfonamide derivatives ELI LILLY AND COMPANY (US) 2005-05-31 — — US claimed
US-20040067984-A1 Cyclopentyl sulfonamide derivatives CANTRELL BUDDY EUGENE (US) 2004-04-08 — — US claimed
EP-1334087-A1 CYCLOALKYLFLUOROSULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2003-08-13 — — EP claimed
WO-2002032858-A1 CYCLOALKYLFLUOROSULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2002-04-25 — — WO claimed
US-6900353-B2 Cyclopentyl sulfonamide derivatives ELI LILLY AND COMPANY (US) 2005-05-31 — — US disclosed
US-20040067984-A1 Cyclopentyl sulfonamide derivatives CANTRELL BUDDY EUGENE (US) 2004-04-08 — — US disclosed
EP-1334087-A1 CYCLOALKYLFLUOROSULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2003-08-13 — — EP disclosed
WO-2002032858-A1 CYCLOALKYLFLUOROSULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2002-04-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040067984-A1 Cyclopentyl sulfonamide derivatives GRIN2A, GRIN1, GRIK5 ADAM17 3636/4885MMP2 4819/4885MMP9 4803/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.